Existing investor Biocon bought more shares in a $65.4m offering that involved the immuno-inflammatory disorder drug developer floating at the bottom of its range.
Equillium, a US-based autoimmune and inflammatory disorder therapy developer that counts biopharmaceutical company Biocon as an investor, has secured $65.4m in an initial public offering on the Nasdaq Global Market.
The IPO consisted of 4.67 million shares priced at $14.00, at the foot of the offering’s $14 to $16 range, giving the company a market capitalisation of about $236m.
Joint book-running managers Jefferies, Leerink Partners and Stifel, Nicolaus & Company have a 30-day option to buy another $9.8m of…
